What investigations are recommended for suspected hepatoblastoma in a child, and what are the differential diagnoses for a pediatric hepatic mass?

Investigations for Hepatoblastoma

For suspected hepatoblastoma in a child, obtain serum alpha-fetoprotein (AFP) and abdominal ultrasound as initial investigations, followed by contrast-enhanced MRI for detailed staging and chest CT to evaluate for metastases.

Essential Diagnostic Workup

Initial Laboratory Testing

• Serum alpha-fetoprotein (AFP) is the critical tumor marker 1

  • AFP is highly sensitive for hepatoblastoma and typically markedly elevated 1
  • AFP elevation often precedes ultrasound detection 1
  • Must interpret AFP in context of age-specific normal values (physiologically elevated in infancy, declining through first years of life) 1
  • Serial AFP measurements every 2-4 weeks help distinguish pathological elevation from normal variation 1
  • Critical caveat: AFP levels should be compared to age-appropriate reference ranges, as normal pediatric values differ significantly from adult values 1

• Additional laboratory work:

  • Liver function tests (usually normal in hepatoblastoma) 2
  • Beta-hCG in infants 2
  • Complete blood count

Imaging Protocol

First-line imaging:

• Abdominal ultrasonography is the initial modality of choice 3, 2
  • Confirms hepatic location of mass
  • Differentiates solid from cystic lesions
  • Evaluates vascular involvement (portal/hepatic thrombosis suggests malignancy) 2
  • Assesses for hypervascular patterns

Definitive staging imaging:

• Contrast-enhanced abdominal MRI for detailed tumor characterization and surgical planning 3, 4

  • Provides superior soft tissue resolution
  • Essential for PRETEXT staging (Pretreatment Extent of Disease system) 3
  • Evaluates vascular involvement, multifocal disease, and future liver remnant 4

• Chest CT to detect pulmonary metastases 3

  • Mandatory for complete staging
  • Hepatoblastoma can metastasize to lungs

Alternative: CT may be used instead of MRI depending on patient age, clinical stability, and equipment availability 2

Histological Confirmation

• Biopsy may be omitted in typical cases: children aged 6 months to 3 years with markedly elevated AFP and characteristic imaging findings 5
• Biopsy is essential for atypical presentations, older children, or when AFP is not significantly elevated 5

Differential Diagnoses for Pediatric Hepatic Mass

Age-Based Differential Approach

Under 3 years of age 2:

• Hepatoblastoma (most common malignant tumor)
• Infantile hemangioma (most common benign tumor)
  • Hypervascular on ultrasound
  • AFP normal or mildly elevated 1
• Mesenchymal hamartoma (cystic appearance)
• Hemangioendothelioma

Over 3 years of age 2, 6:

• Hepatocellular carcinoma (HCC)
  • Often associated with underlying liver disease 6
  • Elevated AFP (though typically lower than hepatoblastoma) 7
  • More common in older children and adolescents
• Fibrolamellar carcinoma
  • Occurs in adolescents without cirrhosis 6
  • Key distinguishing feature: AFP is NOT elevated 6
  • Contains characteristic T2-hypointense fibrous scar 6
• Focal nodular hyperplasia
• Hepatic adenoma
• Undifferentiated (embryonal) sarcoma
  • Appears cystic on CT/MRI but solid on ultrasound 6
  • Contains mucoid components

Other Important Differentials Across All Ages

Malignant:

• Epithelioid hemangioendothelioma (multifocal vascular tumor with confluent peripheral nodules and capsular retraction) 6
• Angiosarcoma (rare, shows hemorrhage) 6
• Embryonal rhabdomyosarcoma of biliary tree (under 5 years, intraductal growth pattern) 6
• Metastatic disease (neuroblastoma, Wilms tumor, lymphoma)

Benign/Pseudotumors:

• Hepatic abscess
• Hematoma
• Focal nodular hyperplasia (associated with portacaval fistula) 2

Key Distinguishing Features

Clinical Context

• Age: Hepatoblastoma peaks at 18 months (95% before age 4) 3; HCC more common after age 5 7
• Underlying liver disease: Suggests HCC rather than hepatoblastoma 6
• Low birth weight: Risk factor for hepatoblastoma 3
• Genetic syndromes: Beckwith-Wiedemann syndrome, Simpson-Golabi-Behmel syndrome, familial adenomatous polyposis, trisomy 18 predispose to hepatoblastoma 3

Laboratory Differentiation

• Markedly elevated AFP (>100,000 ng/mL): Strongly suggests hepatoblastoma over HCC in children >5 years 7
• Normal AFP: Consider fibrolamellar carcinoma, sarcoma, or benign lesions 6

Imaging Characteristics

• Predominantly solid mass: Hepatoblastoma or HCC
• Cystic components: Mesenchymal hamartoma, undifferentiated sarcoma
• Hypervascular: Hemangioma, focal nodular hyperplasia, hemangioendothelioma
• Central scar (non-enhancing): Fibrolamellar carcinoma 6

Critical Management Points

After initial workup, refer immediately to a specialized pediatric oncology center with multidisciplinary team including pediatric oncologists, hepatobiliary surgeons, and radiologists 2. Early detection through screening in high-risk populations (predisposing syndromes) significantly improves outcomes, with 5-year survival exceeding 80-90% in localized disease 3.